BioWorld

Feb. 8, 2002

Actelion Misses Endpoint In Chronic Heart Failure Study

The failure of Tracleer to meet primary endpoints in a Phase III trial of chronic heart failure patients could be a blessing in disguise for Switzerland-based Actelion Ltd. (BioWorld Today) Read More

Immunex, Genesis Form Pact To Research, Develop Molecules

Long-Sought Glaucoma Finally Found, Along With Slow-Onset Blindness-Provoking Mutations

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...